GANX Gain Therapeutics Inc

$GANX I can't keep up with much of the discussion today and I sincerely hope someone would have already pointed this out, but seeing some of some of the uninformed posts twlls me otherwise. The changes to the protocol are because they are following partner feedback. They requested it, they already told us that. It is still 111 patients with 35 in the dose ranging part of the study, which has always been there, they simply elaborated on it. The 35 people deternine the proper dosing. They are still taking UPDRS scores and using wearables for exploratory endpoints. They are for sure still looking for efficacy, common sense. You should reasonably assume they have not made a single move without consulting with partners. Beyond that, if you think this study is being designed with Gain actually anticipating them being the ones reading it out, I have a bridge to sell you. Stay the course or sell. It's your choice.

$GANX What I don’t understand is why some people blame bullish shareholders for their losses. Being optimistic isn’t the same as misleading others. Nobody forced anyone to buy or hold. Investing comes with risks, and we all own our decisions. I’ve chosen to hold until next year’s Phase 2 results. If it pays off, great. If not, I’ll accept the outcome. But here’s what I also don’t understand: Why do others get upset whenever management is criticized? Believing in a company doesn’t mean blindly defending it. We have every right to question the poor communication, lack of clarity on Phase 2 funding, biomarker updates, and weak PR. I believe these issues have hurt investor confidence and contributed to the stock’s decline. I’m frustrated, but I haven’t lost hope. Merck’s $1.3B deal for $SLN reminds us how quickly things can change in biotech. Nothing is guaranteed, but maybe one day it’ll be our turn. Until then, I’ll take responsibility for my decision, not someone else’s.

$GANX i dont care if this stock goes up or down. I just want the drug to work and be ready for sale. My family need this drug.

$GANX I'm not sure an argument exists that could realistically dispute the fact Roche has already decided on Gcase as a target and already initiated that land grab. Can you imagine doing the recent deals they have, and not wanting to own or license the sole safe and efficacious phase 2 ready backbone disease modifying drug with multiple biomarkers. One whose progress we must assume they have been closely following for years now. Seems fairly self evident and just plain common sense to me. I would wager the proverbial beer they have an upfront seat at the table, along with some others. DYDD

$GANX I picked up an additional 50,000 shares between Monday and today. Definitely is a little unnerving. But I’m continuing to believe in the science and patients disease being reversed. The market cap here seems awfully undervalued I feel at this point. This is just more of a common sense investment for me. Swim at your own risk, but don’t be surprised if this thing bumps up pretty quickly from this price.

$GANX If you ever wonder what Magellan is up to they are obviously continuing to update it's capabilities.

$GANX They have and they ironically are speculated to have invited the Gain team over to their headquarters yeara ago, Mathias and others spent a couple days with them apparently at their request. I believe Khalid himself and possibly another board member have long standing ties to them. In fact, it wouldn't surprise me if they previously were close to a deal with Gain. but it failed to happen. Perhaps the gating factor has now been resolved with years of subsequent safety and efficacy data, along with a now second drug behind it. Their recent deals targeting Gcase are highly telling. To invest all that money and not have an interest in the only safe, orally available, efficacious phase 2 ready drug that is disease modifying and treats source versus symptoms, would be a pretty flawed strategy in my mind. If and when something may happen, nobody should be surprised. Their actions and investments speak directly to what they clearly believe is the key to unlocking a cure and treatments for PD... Only issue is how to best assess it, because there is no comparator, no drug has ever demonstrated an MOA like rexacerat. There simply are no comps, it is entirely new science, a major breakthrough.

$GANX Had an interesting discussion with someone in the space about these two slides. They said the industry is starting to get behind the connection behind GluSph and Parkinson’s. Remember less than a year ago this was first discussed by our KOLs. If we can improve Mitochondrial and Lysosomal dysfunction and stop the aggregation of alpha-synuclein we have a huge winner. Plus if the 360 day data shows the GluSph stayed steady at the 90 day level this will be the correlation with stable UPDRS numbers. While I doubt the biomarker data at 360 days gives us the valuation we deserve its another data point to watch for.

$GANX Its amazing how the scientific community has moved to exactly where we already are.

$GANX I bought in for a reason and my reasons haven’t changed.. But it’s unacceptable to leave shareholders in complete limbo while the stock price drifts and the threat of dilution hangs over our heads. There should be some kind of statement, at least drop a hint of some kind to keep investors engaged, don’t know what they could do at the moment, but the current situation is untenable.

$GANX stock goes from 11 to 10 to 9… 8… 7… 6… 5… 4…3…2… 1.15… Up to 1.3 And I feel like I won the lottery 😂😎

$GANX WTF. I’ve been running the roads all day and haven’t been able to pay attention, but from the chatter today you would think this was a penny stock being run out of somebody’s garage. The management team at gain are legit and have reputations to uphold. They can’t come out and say they’ve cured Parkinson’s from a small phase one. I don’t think gene was lying when he stated. “Day 360 nobody’s md-updrs scores went above baseline “ “Very active business development effort with multiple parties “ “Very comfortable from a partnering perspective “. Here is the key management background in the comments

$GANX if we rally hard tomorrow, I expect a Monday announcement. Bio deals happen over weekends.

$GANX recruited Jeanette Weidner as its new Vice President, Finance, effective Oct 28, with a $275K salary and equity grant.

$GANX Below is GANX's entire RSI history on the 8-hour timeframe. As you can see, it has never been this oversold since IPO. A stock is considered oversold when the RSI is under 30. 8h RSI for GANX is currently at 18.95. This is oversold and then some. Keep in mind similar RSI reads were/are printing across the biotech sector. Altimmune was recently at 19 as well—2nd time in 7 years—but has since started recovering (it's a much more advanced bio with a $0.5B cash pile). Even bios with charts in an uptrend were printing 8-hour oversold RSIs close to 20 (FATE, ALLO, OCGN).

$GANX i remember the clowns coming to the immu forum on the goldman downgrade to 5 and they were all mysteriously absent not long after at 88 thank to dr islam. u gotta laugh at the world we live in where these people can post their opinions no matter how stupid they are and not ever have to answer for them later. luv the ole interweb! ;) still wake me at 10, maybe 9 .

$GANX Gene’s been silent for weeks. That means either (1) he’s working on a deal or (2) he’s grossly incompetent. 25 years in the business and this is his best shot so I remain in the (1) camp.

$GANX If you’re scared, you can simply sell and move on. If you choose to stay, then stop the constant crying and complaining. Every time the stock drops a few cents, some of you act like the company is going bankrupt. I’m not happy with management either, and I believe they’re partly responsible for where we are today. The lack of clarity around Phase 2 funding is a legitimate concern, and I think it’s what’s worrying a lot of investors. And to those constantly telling everyone to sell, if we wanted to sell, we would’ve sold at $4, not now.

$GANX market (especially small cap bio land) does not like speculation and that is where we are. Too many questions…management needs to provide answers, hopefully soon 😅

$GANX 13fs are starting to get filed. On the 27th, a new 20K position from BOKF, NA, which is the main banking subsidiary of BOK Financial Corporation, a regional financial services company traded on NASDAQ. Not a huge position of course but I also appreciate singles in addition to home runs (whales).